Allogenic Anti-CD19 gamma delta CAR-T cell therapy (TC BioPharm)

N/A

Report date: 2022/11/02 11:30:07

Base Information

Drug NameAllogenic Anti-CD19 gamma delta CAR-T cell therapy (TC BioPharm)

Drug Alias NameCD19-targetting chimeric antigen receptor γδ T cell therapy (TC BioPharm)Anti-CD19 CAR-γδT cell therapy (TC BioPharm)Anti-CD19 γδ CAR-T cell therapy (TC BioPharm)TCB-003

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsHematologic NeoplasmsLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTc Biopharm Ltd

China Registration ClassN/A

Develop Information

Active CompaniesTc Biopharm Ltd

Inactive CompaniesN/A

Active IndicationsHematologic NeoplasmsLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A